NO20071579L - 4-Heteroarylmethyl-substituted phthalazine derivatives - Google Patents

4-Heteroarylmethyl-substituted phthalazine derivatives

Info

Publication number
NO20071579L
NO20071579L NO20071579A NO20071579A NO20071579L NO 20071579 L NO20071579 L NO 20071579L NO 20071579 A NO20071579 A NO 20071579A NO 20071579 A NO20071579 A NO 20071579A NO 20071579 L NO20071579 L NO 20071579L
Authority
NO
Norway
Prior art keywords
formula
crxry
optionally substituted
group
heteroarylmethyl
Prior art date
Application number
NO20071579A
Other languages
Norwegian (no)
Inventor
Niall Morrison Barr Martin
Graeme Cameron Murray Smith
Xiao-Ling Fan Cockcroft
Muhammad Hashim Javaid
Sylvie Gomez
Jr Vincent Ming Lai Loh
Stefano Forte
Keith Allan Menear
Ian Timothy William Matthews
Original Assignee
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0419072.4A external-priority patent/GB0419072D0/en
Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd
Publication of NO20071579L publication Critical patent/NO20071579L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelse med formel (I) for anvendelse ved behandling av kreft eller andre sykdommer som lindres ved behandling av PARP, hvori: A og B sammen representerer en eventuelt substituert sammensmeltet aromatisk ring; X kan være NRx eller CRxRy; hvis X = NRx, da er n 1 eller 2, og hvis X = CRxRy, da er n l; Rx er valgt fra gruppen som består av H, eventuelt substituert C1-20alkyl, C5-20aryl, C3-20heterosyklyl, amido, tioamido, ester, acyl og sulfonylgrupper; Ry er valgt fra H, hydroksy, amino; eller Rx og Ry kan sammen danne en spiro-C3-7sykloalkyl eller heterosyklylgruppe; RC1 og RC2 er uavhengig valgt fra gruppen som består av hydrogen og C1-4alkyl, eller når X er CRxRy, kan RC1, RC2 , Rx og Ry, sammen med karbonatomene til hvilke de er bundet, danne en eventuelt substituert sammensmeltet aromatisk ring; R1 er valgt fra H og halo; og Het er valgt fra: (i) formel (i), hvori Y1 er valgt fra CH og N, Y2 er valgt fra CH og N, Y3 er valgt fra CH, CF og N, hvor kun en eller to av Y1, Y2 og Y3 kan være N; og (ii) formel (ii), hvor Q er 0 eller S. formel (I)A compound of formula (I) for use in the treatment of cancer or other diseases relieved by the treatment of PARP, wherein: A and B together represent an optionally substituted fused aromatic ring; X may be NRx or CRxRy; if X = NRx, then n is 1 or 2, and if X = CRxRy, then n is 1; Rx is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20aryl, C3-20heterocyclyl, amido, thioamido, ester, acyl and sulfonyl groups; Ry is selected from H, hydroxy, amino; or Rx and Ry may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or when X is CRxRy, RC1, RC2, Rx and Ry, together with the carbon atoms to which they are attached, form an optionally substituted fused aromatic ring; R 1 is selected from H and halo; and Het is selected from: (i) formula (i) wherein Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, where only one or two of Y1, Y2 and Y 3 may be N; and (ii) formula (ii) where Q is 0 or S. formula (I)

NO20071579A 2004-08-26 2007-03-26 4-Heteroarylmethyl-substituted phthalazine derivatives NO20071579L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0419072.4A GB0419072D0 (en) 2004-08-26 2004-08-26 Phthalazinone derivatives
US60495604P 2004-08-27 2004-08-27
PCT/GB2005/003343 WO2006021801A1 (en) 2004-08-26 2005-08-26 4-heteroarylmethyl substituted phthalazinone derivatives

Publications (1)

Publication Number Publication Date
NO20071579L true NO20071579L (en) 2007-05-29

Family

ID=35219560

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071579A NO20071579L (en) 2004-08-26 2007-03-26 4-Heteroarylmethyl-substituted phthalazine derivatives

Country Status (11)

Country Link
EP (1) EP1791827A1 (en)
JP (1) JP2008510783A (en)
KR (1) KR20070057859A (en)
AU (1) AU2005276229A1 (en)
BR (1) BRPI0514632A (en)
CA (1) CA2577191A1 (en)
IL (1) IL181408A0 (en)
MX (1) MX2007002318A (en)
NO (1) NO20071579L (en)
NZ (1) NZ553979A (en)
WO (1) WO2006021801A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CA2652167A1 (en) 2006-05-31 2007-12-06 Philip Jones Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp)
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
SI2805945T1 (en) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2008299721A1 (en) * 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
JP5758630B2 (en) 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Pyridazinone derivatives as PARP inhibitors
UY31603A1 (en) * 2008-01-23 2009-08-31 DERIVATIVES OF FTALAZINONA
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
BRPI0923051B1 (en) * 2008-12-19 2022-07-19 Centrexion Therapeutics Corporation CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION, ASTHMA AND COPD, THEIR USE, FORMULATION AND PHARMACEUTICAL COMBINATION INCLUDING THEM
KR101530234B1 (en) 2009-12-17 2015-06-19 베링거 인겔하임 인터내셔날 게엠베하 New ccr2 receptor antagonists and uses thereof
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5646736B2 (en) 2010-05-12 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel CCR2 receptor antagonists, methods for their preparation, and their use as drugs
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
JP5636094B2 (en) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング CCR2 receptor antagonist
JP5721242B2 (en) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel CCR2 antagonist
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CN102372716A (en) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 Phthalazone derivative, its preparation method and application in medicine thereof
KR101242572B1 (en) * 2010-10-12 2013-03-19 한국화학연구원 Phthalazinone derivatives substituted 5-membered heterocyclic aryl, or pharmaceutically acceptable salts thereof, preparation method therof and pharmaceutical composition
KR101528688B1 (en) * 2010-12-02 2015-06-12 상하이 드 노보 파마테크 컴퍼니 리미티드 Heterocyclic derivatives, preparation processes and medical uses thereof
CN103443085B (en) * 2011-03-14 2016-03-23 南京英派药业有限公司 Quinazoline diones and application thereof
EP3925962A1 (en) * 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
CN103130723B (en) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 Poly (aenosine diphosphate glucose pyrophospheralase (ADP)-ribose) polymerase inhibitor
CN102964354B (en) * 2012-11-16 2014-08-13 江苏先声药业有限公司 Thienoimidazole-like derivatives and applications thereof
CN102977040B (en) * 2012-11-20 2015-06-03 浙江工业大学 Method for synthesizing 2-quinoxalinyl dimethylacetal and 2-quinoxalinyl formaldehyde
HUE030613T2 (en) 2012-12-31 2017-05-29 Cadila Healthcare Ltd Substituted phthalazin-1(2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
PT2968316T (en) 2013-03-13 2019-10-29 Forma Therapeutics Inc 2-hydroxy-1-{4-[(4-phenylphenyl)carbonyl]piperazin-1-yl}ethan-1-one derivatives and related compounds as fatty acid synthase (fasn) inhibitors for the treatment of cancer
CN106146492A (en) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 Heterocycle glyoxaline compound, its pharmaceutical composition and its production and use
CN108026087B (en) 2015-07-02 2021-06-04 中枢疗法公司 Citrate salts of aminopyrimidinone derivatives
CN105384684B (en) * 2015-12-16 2018-02-13 辽宁工程技术大学 A kind of preparation method of the picoline of 2 cyano group 6
US11542282B2 (en) 2018-02-28 2023-01-03 The Trustees Of The University Of Pennsylvania Low affinity poly(AD-ribose) polymerase 1 dependent cytotoxic agents
TWI767148B (en) 2018-10-10 2022-06-11 美商弗瑪治療公司 Inhibiting fatty acid synthase (fasn)
CN113382633A (en) 2018-10-29 2021-09-10 福马治疗股份有限公司 Solid forms of (4- (2-fluoro-4- (1-methyl-1H-benzo [ d ] imidazol-5-yl) benzoyl) piperazin-1-yl) (1-hydroxycyclopropyl) methanone
WO2020155141A1 (en) * 2019-02-02 2020-08-06 中国科学院上海有机化学研究所 Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof
CA3145644A1 (en) 2019-07-19 2021-01-28 Astrazeneca Ab Parp1 inhibitors
JP2023524212A (en) 2020-04-28 2023-06-09 ライゼン ファーマシューティカルズ アーゲー Novel compounds useful as poly(ADP-ribose) polymerase (PARP) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3813531A1 (en) * 1987-05-02 1988-11-10 Asta Pharma Ag Novel 2-aminoalkyl-4-benzyl-1-(2H)-phthalazinone derivatives
ZA882639B (en) * 1987-05-02 1988-09-30 Asta-Pharma Aktiengesellschaft New 2-aminoalkyl-4-benzyl-1(2h)-phthalazinone derivatives
CN1136197C (en) * 1996-05-30 2004-01-28 霍夫曼-拉罗奇有限公司 Novel pyridajinone derivatives
GB0026505D0 (en) * 2000-10-30 2000-12-13 Kudos Pharm Ltd Phthalazinone derivatives
WO2002036576A1 (en) * 2000-10-30 2002-05-10 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2004528376A (en) * 2001-05-08 2004-09-16 クドス ファーマシューティカルズ リミテッド Isoquinolinone derivatives as PARP inhibitors
JP3843454B2 (en) * 2002-02-19 2006-11-08 小野薬品工業株式会社 Fused pyridazine derivative compound and drug containing the compound as an active ingredient
AU2003229953A1 (en) * 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
BRPI0408284B8 (en) * 2003-03-12 2021-05-25 Kudos Pharm Ltd phthalazinone derivatives, their use and pharmaceutical composition comprising them

Also Published As

Publication number Publication date
CA2577191A1 (en) 2006-03-02
NZ553979A (en) 2009-05-31
MX2007002318A (en) 2007-04-17
JP2008510783A (en) 2008-04-10
IL181408A0 (en) 2007-07-04
AU2005276229A1 (en) 2006-03-02
KR20070057859A (en) 2007-06-07
EP1791827A1 (en) 2007-06-06
BRPI0514632A (en) 2008-06-17
WO2006021801A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
NO20071579L (en) 4-Heteroarylmethyl-substituted phthalazine derivatives
LU92680I2 (en) OLAPARIB AND SALTS AND SOLVATES THEREOF
MEP14208A (en) Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents
CO6341631A2 (en) DERIVATIVES OF 1,2,4 - OXADIAZOL AND ITS THERAPEUTIC USE
TNSN05212A1 (en) Phthalazinone derivatives
ME01515B (en) Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
MA37712B1 (en) Macrocyclic inhibitors of flaviviridae virus
NO20066055L (en) pyridine derivatives
EA200870344A1 (en) NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL AGENT, INCLUDING SUCH DERIVATIVE AS AN ACTIVE INGREDIENT
TW200833675A (en) Nicotinamide derivatives
EP3812372A3 (en) 7-heterocyclyl substituted sancycline derivatives for treating bacterial, viral and parasitic infections (e.g. malaria) or inflammatory diseases
RS54473B1 (en) Intermediates for the preparation of macrocyclic inhibitors of hepatitis c virus
NO20083427L (en) Cystotoxic agents comprising novel tomaymycin derivatives and their therapeutic use
NO20083358L (en) Piperasinyl derivatives as modulators of chemokine receptor activity
SG156689A1 (en) Intermediate used for preparation of isoxazoline derivative and novel process for preparation of such intermediate
MX2009011212A (en) Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof.
TW200833340A (en) Imidazo [1, 2-b] pyridazine derivatives
CY1109808T1 (en) ARYLYNDEO-PYRIDINES AND ARYLYNDEO-PYRIDYNES AND THEIR USE AS COMPETITORS OF ADENOSIN A2A RECEPTORS
WO2008006969A3 (en) Novel tetracyclic derivatives, process for the preparation thereof and pharmaceutical compositions which contain them
EA201070839A1 (en) NEW DERIVATIVES OF ACYL CYANOPYRROLIDINES
ME00961B (en) Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics
MA35893B1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
GEP20146063B (en) Solid pharmaceutical composition
ATE359782T1 (en) HETEROARYL-SUBSTITUTED PYRROLE(2, 3- B)PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application